The dream of using anti-CD47 drugs to boost chemotherapy in blood cancer patients is unraveling fast. Weeks after Gilead Sciences stopped its phase 3 trial for futility, ALX Oncology has called a halt ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results